Baseline patient and disease characteristics in patients receiving BCMA–directed CAR T-cell therapy
| Baseline characteristics . | BCMA–directed CAR T-cell therapy (N = 99) . |
|---|---|
| Demographics and disease characteristics | |
| Age, median (range) | 63 (34-78) |
| Male sex, n (%) | 62 (63) |
| Multiple myeloma type | |
| IgG, n (%) | 55 (56) |
| IgA, n (%) | 17 (17) |
| Light chain, n (%) | 25 (25) |
| Nonsecretory, n (%) | 2 (2) |
| Year from diagnosis to BCMA therapy, median (range) | 5 (1-15) |
| Previous lines of therapy, median (range) | 6 (1-12) |
| Previous autologous stem cell transplant, n (%) | 67 (68) |
| Acute immune effector cell toxicity | |
| CRS diagnosis, n (%) | 85 (86) |
| CRS grade, n (%) | |
| Grade 1 | 47 (55) |
| Grade 2 | 33 (39) |
| Grade 3 | 5 (6) |
| Grade 4 | 0 (0) |
| ICANS diagnosis, n (%) | 15 (15) |
| ICANS grade, n (%) | |
| Grade 1 | 4 (27) |
| Grade 2 | 8 (53) |
| Grade 3 | 2 (13) |
| Grade 4 | 1 (7) |
| Tocilizumab administration, n (%) | 55 (56) |
| Median doses tocilizumab, range | 1 (1-4) |
| Median days to first tocilizumab dose, range | 3 (0-20) |
| Low-dose corticosteroid use, n (%) (≥10 mg/d dexamethasone) | 33 (33) |
| High-dose corticosteroid use, n (%) (≥500 mg/d methylprednisolone) | 5 (5) |
| BCMA CAR T-cell outcomes, n (%) | |
| Disease relapse | 52 (53) |
| Death | 20 (20) |
| Baseline characteristics . | BCMA–directed CAR T-cell therapy (N = 99) . |
|---|---|
| Demographics and disease characteristics | |
| Age, median (range) | 63 (34-78) |
| Male sex, n (%) | 62 (63) |
| Multiple myeloma type | |
| IgG, n (%) | 55 (56) |
| IgA, n (%) | 17 (17) |
| Light chain, n (%) | 25 (25) |
| Nonsecretory, n (%) | 2 (2) |
| Year from diagnosis to BCMA therapy, median (range) | 5 (1-15) |
| Previous lines of therapy, median (range) | 6 (1-12) |
| Previous autologous stem cell transplant, n (%) | 67 (68) |
| Acute immune effector cell toxicity | |
| CRS diagnosis, n (%) | 85 (86) |
| CRS grade, n (%) | |
| Grade 1 | 47 (55) |
| Grade 2 | 33 (39) |
| Grade 3 | 5 (6) |
| Grade 4 | 0 (0) |
| ICANS diagnosis, n (%) | 15 (15) |
| ICANS grade, n (%) | |
| Grade 1 | 4 (27) |
| Grade 2 | 8 (53) |
| Grade 3 | 2 (13) |
| Grade 4 | 1 (7) |
| Tocilizumab administration, n (%) | 55 (56) |
| Median doses tocilizumab, range | 1 (1-4) |
| Median days to first tocilizumab dose, range | 3 (0-20) |
| Low-dose corticosteroid use, n (%) (≥10 mg/d dexamethasone) | 33 (33) |
| High-dose corticosteroid use, n (%) (≥500 mg/d methylprednisolone) | 5 (5) |
| BCMA CAR T-cell outcomes, n (%) | |
| Disease relapse | 52 (53) |
| Death | 20 (20) |